Idecabtagene vicleucel received the USFDA approval for the treatment of multiple myeloma in adults who were non-responsive to at least four prior kinds of the treatment regimes. Multiple myeloma is at the forefront of hematological diseases with a worldwide incidence of 160,000, having an incidence to mortality ratio of 1: 0.66 according to a recently published study. What is idecabtagene vicleucel? Idecabtagene vicleucel is a novel treatment line for patients suffering from multiple myeloma using their T-cells.
It involves genetic modification of the patient's T-cells to express chimeric antigen receptors (CAR) against B-cell maturation antigen (BCMA) which is found to be expressed in the myeloma cells. The T-cells are through leukapheresis, and then subjected to a customized genetic modification to target and kill myeloma cells. Following this, the modified T-cells are infused back…
